How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

1,210 results for

Primary Genital Herpes

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1. Interventions for men and women with their first episode of genital herpes. (PubMed)

), and the Alternative Medicines Specialised Register (from inception to April 2016). We handsearched a number of relevant journals, searched reference lists of all included studies, databases of ongoing trials, and other Internet databases.We included randomised controlled trials (RCTs) on participants with first-episode genital herpes. We excluded vaccination trials, and trials in which the primary objective assessed a complication of HSV infection.All studies written in English were independently assessed (...) Interventions for men and women with their first episode of genital herpes. Genital herpes is incurable, and is caused by the herpes simplex virus (HSV). First-episode genital herpes is the first clinical presentation of herpes that a person experiences. Current treatment is based around viral suppression in order to decrease the length and severity of the episode.To determine the effectiveness and safety of the different existing treatments for first-episode genital herpes on the duration

Full Text available with Trip Pro

2016 Cochrane

2. WHO guidelines for the treatment of Genital Herpes Simplex Virus

WHO guidelines for the treatment of Genital Herpes Simplex Virus WHO GUIDELINES FOR THE Treatment of Genital Herpes Simplex VirusWHO GUIDELINES FOR THE Treatment of Genital Herpes Simplex Virus WHO Library Cataloguing-in-Publication Data WHO guidelines for the treatment of genital herpes simplex virus I.World Health Organization. ISBN 978 92 4 154987 5 Subject headings are available from WHO institutional repository © World Health Organization 2016 All rights reserved. Publications of the World (...) epidemiology and burden 5 Why new guidelines for the prevention, treatment and management of STIs? 5 Approach to the revision of STI guidelines 6 References 8 WHO guidelines for the treatment of genital herpes simplex virus 9 1. Introduction 9 1.1 Epidemiology, burden and clinical considerations 9 Clinical presentation 9 Laboratory diagnosis 10 1.2 Rationale for new recommendations 10 1.3 Objectives 10 1.4 Target audience 10 1.5 Structure of the guidelines 11 2. Methods 12 2.1 Guideline Development Group

2016 World Health Organisation Guidelines

3. Genital Herpes Infection: Serologic Screening

summaries are one-page documents that provide guidance to primary care clinicians for using recommendations in practice. This summary is intended for use by primary care clinicians. ( ) Current as of: December 2016 Internet Citation: Final Update Summary: Genital Herpes Infection: Serologic Screening . U.S. Preventive Services Task Force. December 2016. https://www.uspreventiveservicestaskforce.org/Page/Document/UpdateSummaryFinal/genital-herpes-screening1 • • • • USPSTF Program Office • 5600 Fishers (...) Genital Herpes Infection: Serologic Screening Final Update Summary: Genital Herpes Infection: Serologic Screening - US Preventive Services Task Force Search USPSTF Website Text size: Assembly version: 1.0.0.308 Last Build: 11/16/2018 6:27:19 PM You are here: Final Summary Genital Herpes Infection: Serologic Screening Release Date: November 2016 Recommendation Summary Population Recommendation Grade Asymptomatic adolescents and adults, including those who are pregnant The USPSTF recommends

2016 U.S. Preventive Services Task Force

4. How well do antivirals shorten genital herpes pain duration?

shorten genital herpes pain duration? Evidence-based answer: Oral and intravenous (IV) acyclovir each shorten the duration of pain for a first primary outbreak of herpes by about 50%; topical acyclovir shortens it by about 25% (strength of recommendation [SOR]: B, small randomized controlled trials [RCTs] with some methodological flaws). Oral valacyclovir and famcyclovir are equivalent to oral acyclovir. Adding topical acyclovir to oral acyclovir doesn’t produce additional benefit (SOR: B, RCTs (...) How well do antivirals shorten genital herpes pain duration? How well do antivirals shorten genital herpes pain duration? Toggle navigation Shared more. Cited more. Safe forever. Toggle navigation View Item JavaScript is disabled for your browser. Some features of this site may not work without it. Search MOspace This Collection Browse Statistics How well do antivirals shorten genital herpes pain duration? View/ Open Date 2015-03 Contributor Format Metadata Abstract Q: How well do antivirals

2015 Clinical Inquiries

5. Management of Genital Herpes in Pregnancy

of Southampton, Consultant in Genitourinary and HIV Medicine, Solent NHS Trust3 Contents 1. Objective and scope 4 2. Search strategy 5 3. Background 6 4. Management of pregnant women with first episode genital herpes 8 5. Management of pregnant women with recurrent genital herpes 10 6. Management of women with primary or recurrent genital lesions at the onset of labour 11 7. Genital herpes in preterm prelabour rupture of membranes 13 (before 37 +0 weeks of gestation) 8. Management of HIV-positive women (...) of genital herpes infection in uninfected mothers during pregnancy, please see the transmission prevention advice in the 2014 BASHH guideline on the management of genital herpes (currently undergoing consultation). The population covered by this guideline includes pregnant women with a suspected or confirmed diagnosis of genital herpes simplex infection in primary or secondary care. This guideline is aimed at healthcare professionals working in maternity units and departments offering level 3 care

2014 Royal College of Obstetricians and Gynaecologists

6. Comparison of Acyclovir and Multistrain Lactobacillus brevis in Women with Recurrent Genital Herpes Infections: a Double-Blind, Randomized, Controlled Study. (PubMed)

Comparison of Acyclovir and Multistrain Lactobacillus brevis in Women with Recurrent Genital Herpes Infections: a Double-Blind, Randomized, Controlled Study. We performed a randomized double-blind controlled trial to compare the efficacy and safety of multistrain probiotic and acyclovir in women patients with recurrent genital herpes simplex virus type 2 (HSV-2) infections. Eighty-one patients enrolled in the study were being treated with multistrain Lactobacillus brevis one vaginal capsule (...) , and no side effect of L. brevis are valuable properties of probiotic therapy compared with acyclovir. Therefore, we concluded that multistrain L. brevis could play an important role in suppression of recurrent genital herpes simplex virus infection.

2019 Probiotics and antimicrobial proteins

7. Primary Genital Herpes

Primary Genital Herpes Primary Genital Herpes Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 Primary Genital Herpes Primary Genital (...) Herpes Aka: Primary Genital Herpes , Acute Genital Herpes , Initial Genital Herpes From Related Chapters II. Symptoms: Prodrome (precedes genital lesions by hours to days) Genital symptoms Focal, genital pain, s, burning, itching Lesions occur at the perineum, buttock, upper thigh or perianal area Systemic symptoms Malaise Myalgias III. Signs: Skin Lesions Lesion development Starts as shallow Umbilicates with central depression Ulcerate early in course s and then re-epitheliazes without scarring

2018 FP Notebook

8. Nasal Immunization Confers High Avidity Neutralizing Antibody Response and Immunity to Primary and Recurrent Genital Herpes in Guinea Pigs (PubMed)

Nasal Immunization Confers High Avidity Neutralizing Antibody Response and Immunity to Primary and Recurrent Genital Herpes in Guinea Pigs Genital herpes is one of the most prevalent sexually transmitted infections in both the developing and developed world. Following infection, individuals experience life-long latency associated with sporadic ulcerative outbreaks. Despite many efforts, no vaccine has yet been licensed for human use. Herein, we demonstrated that nasal immunization (...) with an adjuvanted HSV-2 gD envelope protein mounts significant protection to primary infection as well as the establishment of latency and recurrent genital herpes in guinea pigs. Nasal immunization was shown to elicit specific T cell proliferative and IFN-γ responses as well as systemic and vaginal gD-specific IgG antibody (Ab) responses. Furthermore, systemic IgG Abs displayed potent HSV-2 neutralizing properties and high avidity. By employing a competitive surface plasmon resonance (SPR) analysis combined

Full Text available with Trip Pro

2016 Frontiers in immunology

9. Maintenance Dose Study of GEN-003 in Subjects With Genital Herpes Infection

: Parallel Assignment Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) Primary Purpose: Treatment Official Title: A Randomized, Placebo-controlled, Double-blind Study to Assess the Efficacy and Safety of a Maintenance Dose of GEN-003 in Subjects With Genital Herpes Infection Actual Study Start Date : May 24, 2017 Actual Primary Completion Date : December 22, 2017 Actual Study Completion Date : June 11, 2018 Resource links provided by the National Library of Medicine (...) , phosphatidylcholine, and cholesterol. Other Name: Adjuvant Placebo Comparator: Placebo 0.9% normal saline administered as a 0.5mL intramuscular (IM) injection Other: 0.9% normal saline Placebo Outcome Measures Go to Primary Outcome Measures : Percentage of Days With Genital Herpes Lesions [ Time Frame: The 6-month period after vaccination ] Subject-reported via electronic diary Secondary Outcome Measures : Number of Genital Herpes Recurrences [ Time Frame: The 6-month period after vaccination ] Subject-reported

2017 Clinical Trials

10. Novel Role for Interleukin-17 in Enhancing Type 1 Helper T Cell Immunity in the Female Genital Tract following Mucosal Herpes Simplex Virus 2 Vaccination (PubMed)

Novel Role for Interleukin-17 in Enhancing Type 1 Helper T Cell Immunity in the Female Genital Tract following Mucosal Herpes Simplex Virus 2 Vaccination It is well established that interferon gamma (IFN-γ) production by CD4+ T cells is critical for antiviral immunity against herpes simplex virus 2 (HSV-2) genital infection. However, the role of interleukin-17A (IL-17A) production by CD4+ T cells in HSV-2 antiviral immunity is yet to be elucidated. Here we demonstrate that IL-17A plays (...) an important role in enhancing antiviral T helper type 1 (Th1) responses in the female genital tract (FGT) and is essential for effective protection conferred by HSV-2 vaccination. While IL-17A did not play a critical role during primary genital HSV-2 infection, seen by lack of differences in susceptibility between IL-17A-deficient (IL-17A-/-) and wild-type (WT) C57BL/6 mice, it was critical for mediating antiviral responses after challenge/reexposure. Compared to WT mice, IL-17A-/- mice (i) infected

Full Text available with Trip Pro

2017 Journal of virology

11. Primary herpes simplex infection with genital and extra-genital lesions mimicking disseminated gonococcal disease. (PubMed)

Primary herpes simplex infection with genital and extra-genital lesions mimicking disseminated gonococcal disease. 24930808 2015 09 21 2015 01 13 1365-2133 172 1 2015 Jan The British journal of dermatology Br. J. Dermatol. Primary herpes simplex infection with genital and extra-genital lesions mimicking disseminated gonococcal disease. 278-80 10.1111/bjd.13183 Maroñas-Jiménez L L Dermatology Department, 12 de Octubre University Hospital, Madrid, Spain. lydia.maroasjimenez@gmail.com. Menis D D (...) Delgado-Márquez A M AM Zarco-Olivo C C Ortiz de Frutos F J FJ eng Case Reports Letter 2014 11 27 England Br J Dermatol 0004041 0007-0963 IM Adult Diagnosis, Differential Female Gonorrhea diagnosis Herpes Genitalis diagnosis Herpes Simplex diagnosis Humans 2014 6 17 6 0 2014 6 17 6 0 2015 9 22 6 0 ppublish 24930808 10.1111/bjd.13183

2014 British Journal of Dermatology

12. Detection of Herpes Simplex Virus Type 2 (HSV-2) -Specific Cell-Mediated Immune Responses in Guinea Pigs During Latent HSV-2 Genital Infection (PubMed)

Detection of Herpes Simplex Virus Type 2 (HSV-2) -Specific Cell-Mediated Immune Responses in Guinea Pigs During Latent HSV-2 Genital Infection Genital infections with herpes simplex virus type 2 (HSV-2) are a source of considerable morbidity and are a health concern for newborns exposed to virus during vaginal delivery. Additionally, HSV-2 infection diminishes the integrity of the vaginal epithelium resulting in increased susceptibility of individuals to infection with other sexually (...) transmitted pathogens. Understanding immune protection against HSV-2 primary infection and immune modulation of virus shedding events following reactivation of the virus from latency is important for the development of effective prophylactic and therapeutic vaccines. Although the murine model of HSV-2 infection is useful for understanding immunity following immunization, it is limited by the lack of spontaneous reactivation of HSV-2 from latency. Genital infection of guinea pigs with HSV-2 accurately

Full Text available with Trip Pro

2016 Journal of immunological methods

13. Vaccination with the Secreted Glycoprotein G of Herpes Simplex Virus 2 Induces Protective Immunity after Genital Infection (PubMed)

Vaccination with the Secreted Glycoprotein G of Herpes Simplex Virus 2 Induces Protective Immunity after Genital Infection Herpes simplex virus 2 (HSV-2) infects the genital mucosa and establishes a life-long infection in sensory ganglia. After primary infection HSV-2 may reactivate causing recurrent genital ulcerations. HSV-2 infection is prevalent, and globally more than 400 million individuals are infected. As clinical trials have failed to show protection against HSV-2 infection, new (...) vaccine candidates are warranted. The secreted glycoprotein G (sgG-2) of HSV-2 was evaluated as a prophylactic vaccine in mice using two different immunization and adjuvant protocols. The protocol with three intramuscular immunizations combining sgG-2 with cytosine-phosphate-guanine dinucleotide (CpG) motifs and alum induced almost complete protection from genital and systemic disease after intra-vaginal challenge with HSV-2. Robust immunoglobulin G (IgG) antibody titers were detected

Full Text available with Trip Pro

2016 Viruses

14. Intra-vaginal Zinc Oxide Tetrapod Nanoparticles as Novel Immunoprotective Agents against Genital Herpes (PubMed)

a reinfection. We also found that ZOTEN exhibits strong adjuvant-like properties, which is highly comparable with alum, a commonly used adjuvant. Overall, to our knowledge, our study provides the very first evidence for the protective efficacy of an intravaginal microbicide/vaccine or microbivac platform against primary and secondary female genital herpes infections.Copyright © 2016 by The American Association of Immunologists, Inc. (...) Intra-vaginal Zinc Oxide Tetrapod Nanoparticles as Novel Immunoprotective Agents against Genital Herpes Virtually all efforts to generate an effective protection against the life-long, recurrent genital infections caused by HSV-2 have failed. Apart from sexual transmission, the virus can also be transmitted from mothers to neonates, and it is a key facilitator of HIV coacquisition. In this article, we uncover a nanoimmunotherapy using specially designed zinc oxide tetrapod nanoparticles (ZOTEN

Full Text available with Trip Pro

2016 Journal of immunology (Baltimore, Md. : 1950)

15. Comparative Effectiveness of Treatment Options for Genital Herpes Infection to Reduce Adverse Pregnancy Outcomes

: 1200 participants Observational Model: Cohort Time Perspective: Prospective Official Title: Comparative Effectiveness of Treatment Options for Genital Herpes Infection in Pregnant Women to Reduce Adverse Pregnancy Outcomes Actual Study Start Date : March 14, 2017 Estimated Primary Completion Date : August 2019 Estimated Study Completion Date : July 2020 Resource links provided by the National Library of Medicine related topics: Groups and Cohorts Go to Group/Cohort Cohort A Women with genital (...) herpes receiving treatment before the 3rd trimester Cohort B Women with genital herpes receiving treatment after the 3rd trimester Cohort C Women with untreated genital herpes Cohort D Women (controls) with neither genital herpes nor treatment Outcome Measures Go to Primary Outcome Measures : Preterm Delivery [ Time Frame: birth before 37 completed weeks of gestation ] Eligibility Criteria Go to Information from the National Library of Medicine Choosing to participate in a study is an important

2016 Clinical Trials

16. Genital Herpes

infected with , virus remains latent in spinal nerve roots until outbreaks Outbreaks may be triggered with various stressors IV. Precautions Genital Herpes is asymptomatic in 65-90% of patients Asymptomatic viral shedding occurs on 10-20% of all days (regardless of outbreak) Most common in the first year of infection, but frequent shedding may persist for years V. Symptoms Primary infection ( ) May be associated with fever, malaise and adenopathy HSV DNA migrates up the infected axon to the affected (...) spinal cord sensory HSV persists in the sensory life long, dormant until next outbreak On periodic reactivation, HSV DNA migrates down axon and erupts again See ( ) Prodromal symptoms (duration hours to days) Focal, genital pain, s, burning, itching Lesions occur at the perineum, buttock, upper thigh or perianal area Vesicular (duration 2 weeks for primary herpes, and 6-12 days for secondary herpes) s erupt at the areas of pain and ultimately ulcerate and then heal Course First outbreak (primary

2018 FP Notebook

17. Genital Herpes in Pregnancy

Genital Herpes in Pregnancy Aka: Genital Herpes in Pregnancy II. Findings See See See III. Management: Pregnancy (> 36 weeks gestation) Treat primary infections on protocol Culture and lesion every 3-5 days until negative if indicated See below for prevention of transmission indications Culture positive All women with active lesions IV. Complications: Vertical transmission V. Prevention: Neonatal Herpes Simplex Virus transmission Prevent transmission from HSV positive partner Abstinence or use during (...) outbreak References VI. References Images: Related links to external sites (from Bing) These images are a random sampling from a Bing search on the term "Genital Herpes in Pregnancy." Click on the image (or right click) to open the source website in a new browser window. Related Studies (from Trip Database) Related Topics in Obstetrics About FPnotebook.com is a rapid access, point-of-care medical reference for primary care and emergency clinicians. Started in 1995, this collection now contains 6656

2018 FP Notebook

18. Recurrent Genital Herpes

predictive of more frequent recurrences Severe primary outbreak Male gender More frequent initially, decrease over time Exposure to provocative factors Stressful situations Heat or cold extreme exposure Immunocompromised IX. References Images: Related links to external sites (from Bing) These images are a random sampling from a Bing search on the term "Recurrent Genital Herpes." Click on the image (or right click) to open the source website in a new browser window. Related Studies (from Trip Database (...) Recurrent Genital Herpes Recurrent Genital Herpes Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 Recurrent Genital Herpes Recurrent

2018 FP Notebook

19. Optimal management of genital herpes: current perspectives (PubMed)

Optimal management of genital herpes: current perspectives As one of the most common sexually transmitted diseases, genital herpes is a global medical problem with significant physical and psychological morbidity. Genital herpes is caused by herpes simplex virus type 1 or type 2 and can manifest as primary and/or recurrent infection. This manuscript provides an overview about the fundamental knowledge on the virus, its epidemiology, and infection. Furthermore, the current possibilities (...) of antiviral therapeutic interventions and laboratory diagnosis of genital herpes as well as the present situation and perspectives for the treatment by novel antivirals and prevention of disease by vaccination are presented. Since the medical management of patients with genital herpes simplex virus infection is often unsatisfactory, this review aims at all physicians and health professionals who are involved in the care of patients with genital herpes. The information provided would help to improve

Full Text available with Trip Pro

2016 Infection and drug resistance

20. Genital Herpes: Insights into Sexually Transmitted Infectious Disease (PubMed)

Genital Herpes: Insights into Sexually Transmitted Infectious Disease Etiology, transmission and protection: Herpes simplex virus-2 (HSV-2) is a leading cause of sexually transmitted infections with recurring manifestations throughout the lifetime of infected hosts. Currently no effective vaccines or prophylactics exist that provide complete protection or immunity from the virus, which is endemic throughout the world. Pathology/Symptomatology: Primary and recurrent infections result in lesions (...) and inflammation around the genital area and the latter accounts for majority of genital herpes instances. Immunocompromised patients including neonates are susceptible to additional systemic infections including debilitating consequences of nervous system inflammation. Epidemiology, incidence and prevalence: More than 500 million people are infected worldwide and most reported cases involve the age groups between 16-40 years, which coincides with an increase in sexual activity among this age group. While

Full Text available with Trip Pro

2016 Microbial cell

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>